1. Home
  2. MMA vs XLO Comparison

MMA vs XLO Comparison

Compare MMA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMA

Alta Global Group Limited

HOLD

Current Price

$0.56

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.35

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMA
XLO
Founded
2013
2016
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
49.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MMA
XLO
Price
$0.56
$8.35
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
296.7K
32.9K
Earning Date
05-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.35
$0.46
52 Week High
$2.00
$9.25

Technical Indicators

Market Signals
Indicator
MMA
XLO
Relative Strength Index (RSI) 48.33 56.37
Support Level $0.35 $0.62
Resistance Level $0.71 $9.03
Average True Range (ATR) 0.05 0.40
MACD -0.00 -0.02
Stochastic Oscillator 67.51 56.43

Price Performance

Historical Comparison
MMA
XLO

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: